KR20160114304A - Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient - Google Patents

Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient Download PDF

Info

Publication number
KR20160114304A
KR20160114304A KR1020150040588A KR20150040588A KR20160114304A KR 20160114304 A KR20160114304 A KR 20160114304A KR 1020150040588 A KR1020150040588 A KR 1020150040588A KR 20150040588 A KR20150040588 A KR 20150040588A KR 20160114304 A KR20160114304 A KR 20160114304A
Authority
KR
South Korea
Prior art keywords
skin
extract
hippocampus
external preparation
effect
Prior art date
Application number
KR1020150040588A
Other languages
Korean (ko)
Inventor
이지영
이춘몽
최경혜
이강태
이건국
Original Assignee
주식회사 코리아나화장품
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 코리아나화장품 filed Critical 주식회사 코리아나화장품
Priority to KR1020150040588A priority Critical patent/KR20160114304A/en
Publication of KR20160114304A publication Critical patent/KR20160114304A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to an external skin preparation for improving atopy comprising hippopotamus extract as an active ingredient, which has excellent antibacterial activity against Staphylococcus aureus (Staphylococcus aureus) and is excellent in an effect of inhibiting the expression of inflammatory cytokines, It has excellent function enhancement effect.

Description

TECHNICAL FIELD [0001] The present invention relates to a skin external preparation for improving atopic skin comprising an extract of hippocampus as an effective ingredient. [0002] The present invention relates to a skin external preparation for improving atopic skin,

The present invention relates to an external preparation for skin for improving atopy comprising a sea horse extract as an active ingredient.

In general, the skin is an organ that is always in contact with the external environment, and acts as a protective barrier to prevent moisture loss. The horny layer of the epidermis also exists in the outermost part of the skin and inhibits the loss of moisture and electrolytes outside the skin, thereby preventing the skin from drying and providing an environment in which the skin can perform a normal metabolic process. It also plays an important role in protecting the body from external physical damage, chemical substances, and preventing invasion of bacteria, viruses, etc. into the skin.

Atopic dermatitis is a disease caused by environmental and genetic problems in these skin. Atopic dermatitis is the only disease associated with complex interactions between skin barrier dysfunction and environmental factors such as allergens and microorganisms (Incovaria et al., Clin. Exp. Immunol., 153: 27-29, 2003). All skin cells, including melanocytes and keratinocytes, produce reactive oxygen species (ROS) and reactive nitrogen species (RNS) (Pelle et al., J. Mol. Invest. Dermatol., 124: 793-797, 2005; Kornina and Pastore, Front. Biosci., 1: 123-141, 2005). In addition, ROS produced from skin cells also react with lipid radicals, peroxides, and lipid radicals by reaction with lipid molecules or redox-sensitive lipid metabolism enzymes such as lipoxigenase and cyclooxygenase. , Reactive lipid species such as hydroperoxide, or aldehydes. Atopic dermatitis, a chronic inflammatory disease, disrupts such redox balance leading to overproduction of ROS and RNS and high levels of lipid peroxides, which eventually worsens the disease state and biases towards the Th2-biased immune response (Briganti and Picardo , J. Eur. Acad. Dermatol., 17: 663-669, 2003; Wu et al., Clin. Exp. Immunol., 135: 194-199, 2004).

The inflammatory reactions that appear on the skin appear as redness, tingling, burning, swelling, and changes in tissue, which are physiological and physiologic factors that protect the body from harmful environmental conditions such as intrusion of external substances such as bacteria and mechanical damage Reaction. Typical skin troubles associated with inflammation include atopy and acne. Especially, if you talk about atopy, atopy is characterized by severe itching. When you stimulate the skin, the itching becomes worse. This causes bacterial infections (Staphylococcus aureus, Streptococcus, etc.) and inflammation occurs. One of the important factors in the problem of atopy is the secondary infections and superantigen toxins that occur at this time. Eighty to forty percent of atopic patients have Staphylococcus aureus and Stereptococcus pyogenes , where anti- Staphylococcus , IgE is produced, which is caused by a superantigen toxin that stimulates the T-cell response. More specifically, the superantigen toxin of Staphylococcus aureus selectively stimulates T lymphocytes through antigen presenting cells in Langerhans cells to produce interleukin-1 and TNF-alpha, and stimulates T-cell stimulation It secretes toxin called cytokine in branch cell and causes inflammation. That is, the superantigen toxin promotes the secretion of interleukin-4 and interleukin-5, thereby inhibiting the secretion of IFN-gamma and increasing the number of CLA, thereby promoting the production of IgE. Such IgE causes secretion of histamine from the basophil, and atopic dermatitis is exacerbated.

In general, it is known that atopic dermatitis patients are more susceptible to bacterial, viral, and fungal skin infections than normal people. In particular, the propagation of 90% of atopic patients is the accumulation Staphylococcus aureus (Staphylococcus aureus) in the skin, epithelium of atopic patients is known through many studies that there is a Staphylococcus aureus infection. However, the pathogenesis of staphylococcal infection and proliferation of epithelial cells in these atopic patients is unclear. It is known that the genetic predisposition is due to the high incidence of atopic dermatitis in parents of children with atopic dermatitis, and the incidence of atopic dermatitis is also known to increase as the period of lactation from mother with atopic dermatitis increases

These staphylococcal skin infections are mainly caused by reducing the content of ceramides in the stratum corneum. Atopic dermatitis is caused by dryness of the skin due to the loss of the water retention function of the stratum corneum, resulting in a large amount of keratin. As the skin barrier function is lowered, the stimulating substance enters the stratum corneum and induces stimulation. , Skin allergies and the like are easily occurred, resulting in severe pruritus. Therefore, more than 90% of atopic patients are infected with Staphylococcus aureus, which is caused by scraping because the patient can not tolerate the itching, but the bacterial exotoxin stimulates the body's immune system, causing chemicals that cause allergy, .

In order to solve this problem, currently available methods of treating atopic skin include, but are not limited to, the use of moisturizing agents, the use of tar preparations, the use of a proper or steroid preparation, ultraviolet light treatment, antibiotics such as clindamycin, dicloxacilline, Antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antioxidants, antimicrobial agents, antimicrobial agents, antibiotics such as povidone iodine and triclosan, immunotherapeutic agents, food, fragrance and herbal medicine.

However, Tar formulation has a disadvantage of irritating dry skin due to its alcohol component. Steroid preparations have serious side effects such as rash, change of skin color, hypertension, cataract, etc. Ultraviolet rays are a cause of sunburn, itching, The risk of premature aging and cancer of the skin during sedation and prolonged treatment is high, and antibiotics are mainly used as internal medicine.

 In addition, the antibacterial agent has skin irritation according to the concentration, and the immunity control, inhibitor, etc. are difficult to use because they are not used in the face such as chicken pox, shingles, etc., Herbal therapy, and other fragrance therapies have no adverse effects on their use, but their effects are often insufficient.

Korean Patent Laid-Open No. 10-2009-0043656 discloses an antioxidative composition containing a hippocampus extract and discloses DPPH radical, hydroxyl radical, superoxide radical and peroxyl radical removal activity of hippocampus extract.

Accordingly, the inventors of the present invention prepared a hippocampus fermented extract to confirm the applicability of hippopotamus extract to cosmetics. As a result of measuring the effect of inhibiting inflammatory cytokine expression, antibacterial effect, moisturizing effect and skin barrier function, It was found to be excellent.

It is an object of the present invention to provide an external preparation for skin which contains hippocampus extract and exhibits an inflammatory cytokine expression inhibitory effect, an antibacterial effect, a moisturizing effect, and a skin barrier function enhancing effect.

The invention hippocampus (Hippocampus coronatus ) extract as an active ingredient, and to an external preparation for skin for improving atopic skin.

Preferably, the external preparation for skin has antibacterial activity against Staphylococcus aureus.

Preferably, the external preparation for skin has an inflammatory cytokine expression inhibiting effect.

Preferably, the external preparation for skin has a skin moisturizing effect.

Preferably, the external preparation for skin has a skin barrier function enhancing effect.

Preferably, the external preparation for skin has an atopic skin improving effect.

Preferably, the hippocampus extract is contained in an amount of 0.0001 to 30.0% by weight based on the total weight of the external preparation for skin.

Preferably, the hippocampal extract comprises (a) water, an anhydrous or a lower alcohol having 1-4 carbon atoms, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane, (B) a supercritical extraction method, and (c) an ultrasonic extraction method, wherein the solvent extraction method is selected from the group consisting of a solvent extraction method using an extraction solvent selected from the group consisting of water,

The present invention relates to an external skin preparation for improving atopy comprising a hippocampus extract as an active ingredient, which has excellent antibacterial activity against Staphylococcus aureus (Staphylococcus aureus) (Experimental Example 1), excellent effect of inhibiting inflammatory cytokine expression (Experimental Example 2), the skin moisturizing power was enhanced (Experimental Example 3), and the skin barrier strengthening effect was excellent (Experimental Example 4).

Further, according to the present invention, in order to maximize the efficacy of the hippocampus, the present invention further enhances the antibacterial effect, the inflammatory cytokine expression inhibiting effect, the moisturizing effect, the skin barrier function enhancing effect and the atopic skin improving effect through the ultrasonic and supercritical extraction processes I will.

The hippocampus used as an active ingredient in the external preparation for skin of the present invention is represented by Hippocampus coronatus . The hippocampus is a tibia fish belonging to the genus Meat and is known to live in 36 species worldwide. Body length is 6 ~ 10.5cm. The most prominent feature is that the thorns of the eyes are clear and the base of the dorsal fin (base: the part connected to the organ or the attachment organs and body) is very short. The elongated snout has the same length as the head of the back of the eye. The head is bent at almost right angles to other fishes and the body is composed of many corrugated plates. The head has a tube-like protrusion protruding clearly and a protruding hook in the neck. It lives near the coast. It is distributed in sub-tropical waters such as Korea and Japan.

In the present invention, the hippocampus extract is obtained by extracting from various organs or parts of the hippocampus.

In the present invention, the hippocampal extract is prepared by mixing various extraction solvents, for example, water, anhydrous or lower alcohols having 1-4 carbon atoms (e.g., methanol, ethanol, propanol and butanol), propylene glycol, And at least one extraction solvent selected from the group consisting of glycerin, acetone, diethyl ether, ethyl acetate, butyl acetate, dichloromethane, chloroform, hexane and mixtures thereof. (v / v) ethanol or water, and most preferably 70% (v / v) ethanol.

It is obvious to those skilled in the art that the hippocampus extract of the present invention can be obtained not only by the above-mentioned extraction solvent but also by using other extraction solvent, which exhibits substantially the same effect.

In addition, the hippocampus extract of the present invention includes not only the extract obtained by the above-mentioned extraction solvent, but also the extract obtained through a conventional purification process. For example, decompression by carbon dioxide, extraction by supercritical extraction with high temperature, extraction by extraction using ultrasound, separation by ultrafiltration membrane with constant molecular weight cutoff value, various chromatography (size, charge, hydrophobic or affinity And the active fraction obtained through various purification and extraction methods, such as those extracted by fermentation products using natural or various microorganisms, are also included in the extract of the present invention.

Further, the present invention provides a topical external preparation for skin characterized in that the above extract is obtained by liquid-freezing obtained by cold-pressing and heat-filtration at room temperature, and furthermore, concentrated or lyophilized at reduced pressure.

The supercritical fluid extraction refers to supercritical fluid extraction. Generally, the supercritical fluid is extracted from the liquid and the liquid when the gas reaches the critical point at high temperature and high pressure. (J. Chromatogr. A. 1998; 479: 200-205). In addition, it has been reported that the supercritical fluid has a polarity similar to that of a nonpolar solvent.

Carbon dioxide is a supercritical fluid with both liquid and gaseous nature, with the operation of supercritical fluid equipment reaching its critical pressure and temperature, resulting in increased solubility in fat-soluble solutes. When supercritical carbon dioxide passes through an extraction vessel containing a certain amount of sample, the lipophilic substance contained in the sample is extracted into supercritical carbon dioxide.

When the supernatant carbon dioxide containing a small amount of cosolvent is passed through the sample remaining in the extraction vessel after extracting the lipid-soluble substance, components that were not extracted by pure supercritical carbon dioxide can be extracted.

The supercritical fluid used in the supercritical extraction method of the present invention can effectively extract an active ingredient by using a mixed fluid in which a cosolvent is further mixed with supercritical carbon dioxide or carbon dioxide.

These co-solvents may be used alone or in admixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether.

Most of the extracted samples contain carbon dioxide. Since the carbon dioxide is volatilized into air at room temperature, the extract obtained by the above method can be used as an external preparation for skin, and the cosolvent can be removed with a decompression evaporator.

In addition, the ultrasonic extraction method is an extraction method using energy generated by ultrasonic vibration. Ultrasonic waves can destroy an insoluble solvent contained in a sample in a water-soluble solvent. Due to the high local temperature generated at this time, Since the kinetic energy of the particles is increased, sufficient energy required for the reaction is obtained. By inducing the high pressure by the shock effect of the ultrasonic energy, the mixing efficiency of the substance contained in the sample and the solvent is increased, thereby increasing the extraction efficiency.

As the extraction solvent which can be used for the ultrasonic extraction method, one or a mixture of two or more selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane and diethyl ether can be used. The extracted sample is recovered by vacuum filtration, and the filtrate is recovered, and the extract is removed by a vacuum evaporator and freeze-dried to obtain an extract.

According to the present invention, the hippocampus extract is contained in an amount of 0.0001 to 30.0% by weight based on the total weight of the external preparation for skin, more preferably the hippocampus extract is contained in an amount of 0.01 to 10% by weight based on the total weight of the external preparation for skin do. When the content of the extract is less than 0.0001% by weight, the effect of improving the skin is not exhibited. When the content of the extract is more than 30.0% by weight, the degree of improvement of the skin against the increase of the content is insignificant, It is not even.

Therefore, the external preparation for skin of the present invention comprising hippocampus extract having various functions of the present invention has excellent antimicrobial effect against Staphylococcus aureus, inflammatory cytokine expression inhibiting effect, skin moisturizing effect, skin barrier function enhancing effect, and atopic skin improving effect .

The components included in the composition of the present invention may contain, in addition to the above-mentioned effective components, the components conventionally used in the composition for external application for skin, such as conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, Carrier.

In the case of application to medicines, an inorganic or organic carrier used as an active ingredient of the hippocampus extract according to the present invention may be added to formulate the composition in the form of a solid, semi-solid or liquid, orally or parenterally.

Examples of the agent for oral administration include tablets, pills, tablets, soft capsules, powders, fine granules, powders, emulsions, syrups, fillets and the like. For parenteral administration, injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like may be mentioned. In order to formulate the active ingredient of the present invention, it can be easily formulated according to a conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspending agents and other adjuvants for commercialization can be suitably used.

The compositions of the present invention may be prepared in any of the formulations conventionally manufactured in the art and may be in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, Oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray, but are not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Alkylamido betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

When the composition of the present invention is a soap, a surfactant-containing cleansing formulation or a surfactant-free cleansing formulation, it may be applied to the skin and then wiped off, washed or rinsed with water. The surfactant-containing cleansing formulation may be a cleansing foam, a cleansing water, a cleansing towel and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.

The composition of the present invention may be used alone or in combination, or may be used in combination with other compositions than the present invention. In addition, the composition according to the present invention can be used according to a conventional method of use, and the number of times of use may be varied depending on the skin condition or taste of the user.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Manufacturing example  1: Production of sea horse extract

The horses were washed and shredded, and then refluxed for 3 hours with 70% (v / v) aqueous ethanol solution for 5 hours. After cooling, the mixture was filtered through Whatman # 4 filter paper. The filtered extract was concentrated under reduced pressure and freeze-dried at 50 DEG C or lower.

Manufacturing example  2 to 3: Supercritical  Manufacture of fluid extracts and ultrasonic extracts

The supercritical extract was obtained by extracting with a conventional supercritical extraction method (extracting with ethanol as a co-solvent in a supercritical state under a pressure of about 300 atm at a temperature of about 60 DEG C). Extracts were obtained by extraction using ultrasound (Super Sonic Ultrasonic Device at 25 ° C for 2 hours at 30 ° C). In the case of Production Example 3, ethanol was used as a co-solvent.

Experimental Example  1: Seaweed extract Effect of antimicrobial activity on microorganisms

In order to examine the antimicrobial activity of the hippopotamus extracts extracted in the above production example, a visualization experiment was carried out by paper disc method on Staphylococcus aureus KCTC 1916, KCTC 1928, and EML 5757779 Respectively.

The extract was dissolved in 50% ethanol at a concentration of 100 mg / ml, and then 50 μg of the extract was applied to a paper disk (Whatman NO.1, 8 mm diameter), followed by drying. Then, the strain was placed on an agar plate (0.1 ml) and completely dried for 24 hours. Thereafter, the size of the inhibitory zone was measured to confirm the antimicrobial activity. The results are shown in Table 1 below.

division  Size of inhibition zone (mm) Production Example 1 Production Example 2 Production Example 3 Staphylococcus aureus 14 15 15

Staphylococcus aureus KCTC 1916, KCTC 1928, and EML 5757779 were tested for antimicrobial activity by the paper disc method as shown in Table 1, and the antimicrobial effect was shown in Production Examples 1 to 3.

Experimental Example  2: Inhibitory effect of hippocampal extract on inflammatory cytokine expression by ultraviolet irradiation

Experimental Example 2 was conducted to evaluate the inhibitory effect of inflammatory cytokine expression expressed by ultraviolet irradiation of hippocampus extract obtained through Production Examples 1 to 3, and fibroblasts isolated from human epidermal tissue were treated with 24-well The test plates were plated at 4 x 5 x 10 and adhered for 24 hours. Each well was washed once with PBS and 500 占 퐇 of PBS was added to each well. After irradiating the fibroblasts with 10 mj / cm 2 of ultraviolet light using an ultraviolet B (UVB) lamp (Model: F15TB, UVB 15W, Sankyo Dennki Japan), PBS was removed and cultured in a cell culture medium Medium) was added. The hippopotamus extracts to be evaluated were treated and cultured for 5 hours. 150 [mu] l of the culture supernatant was quantified to quantitate IL-1 [alpha], and the effect of the hippocampal extract in inhibiting the inflammatory cytokine expression was evaluated. The amount of IL-1? Was quantitated using an enzyme-linked immunosorbent assay and the inhibition rate (%) of inflammatory cytokine (IL-1?) Was calculated by the following equation.

[ Equation  One]

Inhibitory rate of inflammatory cytokine expression (%) = [1 - {(St-Bo) / (Bt-Bo)}]

Bo: IL-1? Production in wells without UV irradiation

Bt: IL-1? Production in wells irradiated with ultraviolet light and not treated with sample

St: IL-1? Production in well irradiated and treated with UV

Name of sample Treatment concentration (ppm) Inhibitory rate of inflammatory cytokine expression (%) Production Example 1 100 80.74 1.56 Production Example 2 100 75.18 ± 2.11 Production Example 3 100 82.84 + 1.89 Indomethacin 100 61.23 + - 0.87

According to the results shown in Table 2, the hippocampus extracts prepared according to Preparation Examples 1 to 3 inhibit the production of inflammatory cytokine IL-1α by 80.74%, 75.18%, and 82.84%, respectively, at a concentration of 100 ppm. The hippocampus extract according to the present invention showed an inhibitory rate of inflammatory cytokine expression superior to that of indomethacin, which is an inflammatory cytokine expression inhibitor, at the same concentration. Therefore, it can be seen that the hippocampus extract of the present invention effectively inhibits the inflammation caused by ultraviolet irradiation even at a low concentration.

Formulation Example  1: containing hippopotamus extract Cosmetics  Preparation of composition

Formulation examples including hippocampus extracts were prepared by preparing cosmetic compositions (Formulation Examples 1 to 3) each containing hippocampus extracts of Preparation Examples 1 to 3, and cosmetic compositions containing glycerin and 1,3-butylene glycol as moisturizing agents Comparative Formulation Example 1), and cosmetic composition (Comparative Formulation Example 2) containing neither extract nor moisturizer are shown in Table 3 below.

division ingredient Formulation Example 1 Formulation Example 2 Formulation Example 3 compare
Formulation Example 1
compare
Formulation Example 2
A Production Example 1 3.0 - - - - Production Example 2 - 3.0 - - - Production Example 3 - - 3.0 - - glycerin - - - 5 - 1,3-butylene glycol - - - 5 - EDTA-2Na 0.02 0.02 0.02 0.02 0.02 Purified water to100 to100 to100 to 100 to 100 B Cetostearyl alcohol 2.0 2.0 2.0 2.0 2.0 Glyceryl stearate 1.5 1.5 1.5 1.5 1.5 Microcrystalline 0.7 0.7 0.7 0.7 0.7 Squalane 5.0 5.0 5.0 5.0 5.0 Liquid paraffin 3.0 3.0 3.0 3.0 3.0 Trioctanoin 5.0 5.0 5.0 5.0 5.0 Polysorbate 1.2 1.2 1.2 1.2 1.2 Sorbitan stearate 0.5 0.5 0.5 0.5 0.5 Tocopheryl acetate 0.2 0.2 0.2 0.2 0.2 Cyclomethicone 3.0 3.0 3.0 3.0 3.0 BHT 0.05 0.05 0.05 0.05 0.05 C Incense, preservative Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount

Experimental Example  3: Moisturizing effect of sea horse extract

The moisturizing effect of the cosmetic composition of the above-mentioned formulation example was measured as follows. A, B, and C groups were divided into five groups (A, B, C, D, and E) by randomly dividing 100 healthy men and women who felt skin dry through the questionnaire into 20 groups, (Comparative Formulation Example 1) as a humectant and glycerin and 1,3-butylene glycol as a moisturizing agent (Comparative Formulation Example 1) as a moisturizing agent, and a formulation (Comparative Formulation Example 2) 2 times a day for 4 weeks. The moisturizing effect was evaluated by Corneomater CM820 (Corage + Khazaka, Germany) after every two weeks and after the start of the test. The results are shown in Table 4 below.

division Before use After 2 weeks of use After 4 weeks of use Formulation Example 1 30.15 43.48 50.19 Formulation Example 2 29.15 44.15 51.12 Formulation Example 3 28.98 45.19 53.89 Comparative Formulation Example 1 30.3 42.1 50.9 Comparative Formulation Example 2 28.5 29.4 28.9

As shown in Table 4, it was confirmed that the moisturizing effect of Formulation Examples 1 to 3 containing the sea tangle extract of the present invention was excellent, as compared with Comparative Formulation Example 1 containing other common moisturizing agents.

Experimental Example  4: Skin barrier strengthening effect of sea horse extract

The skin barrier strengthening effect on the cosmetic composition of the above-mentioned formulation example was measured as follows. A questionnaire survey was conducted on 100 healthy men and women who felt skin dryness to be randomly divided into 5 groups (A, B, C, D, E) by 20 persons. After washing the upper arm of the arm, tape stripping After the skin barrier was temporarily weakened, the cosmetic composition of Formulation Examples 1 to 3 was applied to Groups A, B, and C, and glycerin and 1,3-butylene glycol (Comparative Formulation Example 1) was applied to the E group, and the formulation (Comparative Formulation Example 2) containing no separate moisturizing agent was applied to the E group for 2 days, twice each day for 3 days. Moisture evaporation was measured at 0, 48, and 72 hours after tape stripping using Tewameter TM 300 (Courage + Khazaka, cologne, Germany). The results are shown in Table 5 below.

division Water evaporation after 0 hours (%) Moisture Evaporation (%) after 48 hours Evaporation rate (%) after 72 hours Formulation Example 1 100 47.2 32.0 Formulation Example 2 100 48.3 32.8 Formulation Example 3 100 50.2 34.1 Comparative Formulation Example 1 100 49.3 38.2 Comparative Formulation Example 2 100 86.5 72.4

As shown in Table 5, it was confirmed that the skin barrier enhancement effect of Formulation Examples 1 to 3 containing the sea tangle extract of the present invention was excellent, as compared with Comparative Formulation Example 1 containing other humectants.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

Claims (7)

Hippocampus coronatus ) extract as an active ingredient. The method according to claim 1,
Wherein said external preparation for skin has antibacterial activity against Staphylococcus aureus.
The method according to claim 1,
The external preparation for skin for improving atopic skin has the effect of inhibiting the expression of inflammatory cytokines.
The method according to claim 1,
The external preparation for skin for improving atopic skin, wherein the external preparation for skin has a skin moisturizing effect.
The method according to claim 1,
The external preparation for skin for improving atopic skin, wherein the external preparation for skin has a skin barrier function enhancing effect.
6. The method according to any one of claims 1 to 5,
Wherein the hippocampus extract is contained in an amount of 0.0001 to 30.0% by weight based on the total weight of the external preparation for skin.
6. The method according to any one of claims 1 to 5,
The hippopotamus extract comprises (a) water, an anhydrous or a lower alcohol having 1-4 carbon atoms, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane, (B) a supercritical extraction method; and (c) an ultrasonic extraction method. The external skin preparation for atopic skin improvement according to claim 1, wherein the solvent is selected from the group consisting of water,
KR1020150040588A 2015-03-24 2015-03-24 Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient KR20160114304A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150040588A KR20160114304A (en) 2015-03-24 2015-03-24 Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150040588A KR20160114304A (en) 2015-03-24 2015-03-24 Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient

Publications (1)

Publication Number Publication Date
KR20160114304A true KR20160114304A (en) 2016-10-05

Family

ID=57153773

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150040588A KR20160114304A (en) 2015-03-24 2015-03-24 Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient

Country Status (1)

Country Link
KR (1) KR20160114304A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220078031A (en) * 2020-12-03 2022-06-10 김경자 Antimicrobial composition comprising Hippocampus abdominalis extract as effective component

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220078031A (en) * 2020-12-03 2022-06-10 김경자 Antimicrobial composition comprising Hippocampus abdominalis extract as effective component

Similar Documents

Publication Publication Date Title
EP0727217A2 (en) Pharmaceutical composition containing god-type ellagitannin as active ingredient
EP2174648A1 (en) Skin-care compositions and uses thereof
KR102171133B1 (en) Skin external composition comprising centella asiatica extract and papaver rhoeas extract
JP7022700B2 (en) A composition for use in the treatment and / or prevention of juvenile acne vulgaris, which comprises a Harungana madagascariensis leaf extract, and a method for preparing the same.
CN110072516B (en) Cosmetic composition comprising extracts of Chinese medicinal materials as effective ingredients
KR101780486B1 (en) Cosmetic composition comprising echinacea purpurea extract
KR102144568B1 (en) Composition for skin conditioning comprising Morus alba L. extract
KR20190048202A (en) Methods for preparing nanoliposome encapsulating of N-Acetyl glucosamine and Sodium chondroitin sulfate and cosmetic composition containing the same
WO2011115061A1 (en) Hyaluronic acid production promoter
KR102026399B1 (en) Cosmetic composition for skin Humectant comprising Opuntia Ficus-Indica fruit extract and mixed compound of panthenol, hyaluronic acid and betaine
KR20150112103A (en) Compositions for improving skin conditions comprising plant extracts or fractions thereof
US20110135772A1 (en) Skin care agent and compositions thereof
KR101231864B1 (en) Cosmetic composition for improving skin inflammation using deep ocean water
KR20160114304A (en) Skin external composition for improving atopic dermatitis containing extracts of hippocampus coronatus as active ingredient
KR20190021114A (en) Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract
KR101645355B1 (en) Skin external composition for improving atopic dermatitis containing extracts or fractions of allium hookeri as active ingredient
KR20170025542A (en) Cosmetic Composition Comprising Extracts of Bidens bipinnata for Enhancing Skin Tightening and Improving Skin Wrinkle
KR102476671B1 (en) Composition for skin conditioning comprising Scutellaria baicalensis Georgi extract
KR102488864B1 (en) Composition Containing Terminalia Chebula Extract and Artemisia Extract for Controlling Skin Bacterial Flora Growth, or Enhancing Skin Immunity
KR100946584B1 (en) Cosmetic Composition Comprising Poncirus trifoliata fruit extract and Nymphaea caerulea extract
US20020041908A1 (en) Iridacea extracts for stimulating the immune system
JP5155543B2 (en) Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method
KR20160020038A (en) Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil
KR20160000318A (en) Cosmetic composition containing Fir tree oil
KR20150034371A (en) Cosmetic composition comprising the extract of Commelina communis as anti-wrinkle ingredient

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application